What is CoolSculpting?
CoolSculpting operates as a specialized medical technology firm focused on the development and commercialization of non-invasive body contouring treatments. The company utilizes a patented process involving controlled cooling to selectively target and eliminate subcutaneous fat cells without damaging surrounding tissue. Since its inception in 2009, the organization has redefined the aesthetic medicine landscape, offering a clinical alternative to surgical procedures like liposuction. Its market position is characterized by high barriers to entry, supported by extensive intellectual property and a strong network of clinical partnerships that facilitate widespread adoption of its proprietary cooling devices.
How much funding has CoolSculpting raised?
CoolSculpting has raised a total of $136.3M across 3 funding rounds:
Series B
$20.3M
Series D
$25M
Stock Offering
$91M
Series B (2009): $20.3M with participation from Advanced Technology Ventures and Frazier Healthcare Ventures
Series D (2010): $25M led by Frazier Healthcare Ventures, Venrock, and Advanced Technology Ventures
Stock Issuance/Offering (2011): $91M, investors not publicly disclosed
Key Investors in CoolSculpting
Advanced Technology Ventures
A bi-coastal venture capital firm with over 35 years of experience, specializing in building emerging-growth business ventures into market leaders across the healthcare and technology sectors.
Frazier Healthcare Ventures
A prominent investment firm focused on the biopharmaceutical and healthcare industries, providing strategic support to companies developing innovative clinical-stage treatments.
Venrock
A historic venture capital firm headquartered in Palo Alto, known for partnering with founders to scale high-growth technology and healthcare companies through deep industry expertise.
What's next for CoolSculpting?
With the successful completion of its major enterprise-level funding rounds, CoolSculpting is well-positioned to accelerate its research and development pipeline and expand its international market reach. The strategic focus moving forward involves deepening its penetration into the global aesthetics market while exploring potential technological iterations of its core cooling platform. By maintaining a disciplined approach to capital allocation, the company aims to sustain its competitive advantage, ensuring that its non-invasive solutions remain the gold standard for patients seeking effective, safe, and efficient body contouring outcomes in an increasingly crowded medical technology landscape.
See full CoolSculpting company page
